Abstract | OBJECTIVE: METHODS: Population-based cases and controls were recruited from the Baltimore, MD, Philadelphia, PA, and Atlanta, GA, metropolitan areas. Controls (n = 507) reported 2 to 104 headache days/year, and cases (n = 206) reported > or =180 headache days/year. Current and past dietary caffeine consumption and medication use for headache were based on detailed self-report. High caffeine exposure was defined as being in the upper quartile of dietary consumption or using a caffeine-containing over-the-counter analgesic as the preferred headache treatment. RESULTS: In comparison with episodic headache controls, CDH cases were more likely overall to have been high caffeine consumers before onset of CDH (odds ratio [OR] = 1.50, p = 0.05). No association was found for current caffeine consumption (i.e., post CDH) (OR = 1.36, p = 0.12). In secondary analyses, associations were confined to younger (age <40) women (OR = 2.0, p = 0.02) and those with chronic episodic (as opposed to chronic continuous) headaches (OR = 1.69, p = 0.01), without physician consultation (OR = 1.67, p = 0.04) and of recent (<2 years) onset (OR = 1.67, p = 0.03). CONCLUSION:
|
Authors | Ann I Scher, Walter F Stewart, Richard B Lipton |
Journal | Neurology
(Neurology)
Vol. 63
Issue 11
Pg. 2022-7
(Dec 14 2004)
ISSN: 1526-632X [Electronic] United States |
PMID | 15596744
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics
- Pharmaceutical Preparations
- Caffeine
|
Topics |
- Adolescent
- Adult
- Aged
- Analgesics
(chemistry, therapeutic use)
- Beverages
- Caffeine
(adverse effects)
- Case-Control Studies
- Female
- Headache Disorders
(drug therapy, epidemiology, etiology)
- Health Surveys
- Humans
- Male
- Middle Aged
- Pharmaceutical Preparations
- Retrospective Studies
- Risk Factors
- United States
(epidemiology)
|